Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Swedish Orphan Biovitrum AB (publ) - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
SWOBY
Over the counter
2836
www.sobi.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Swedish Orphan Biovitrum AB (publ)
Tryngolza™ (olezarsen) approved in the EU for severe hypertriglyceridaemia (sHTG)
- Nov 17th, 2026 1:22 am
Sobi to present new gout data at ACR Convergence 2026
- Nov 3rd, 2026 1:00 am
Börje Ekholm is proposed as new Chair of the Sobi Board of Directors
- Oct 29th, 2026 3:47 pm
Late-breaking Phase 3 REDUCE-2 data show clinically meaningful and durable serum urate lowering with pozdeutinurad
- Oct 29th, 2026 1:20 am
Sobi (OM:SOBI) Stock Price Trails Strong Q3 Earnings Momentum
- Oct 28th, 2026 2:09 pm
Swedish Orphan Biovitrum (BIOVF) Tops Q3 Earnings and Revenue Estimates
- Oct 27th, 2026 4:10 am
Sobi Q3 2026 report: Underpinning a strong growth momentum
- Oct 27th, 2026 2:30 am
Sobi to present new Aspaveli®/Empaveli® data at ASN Kidney Week 2026
- Oct 19th, 2026 2:43 am
Sobi receives positive CHMP opinion for TRYNGOLZA® (olezarsen) for the treatment of severe hypertriglyceridemia (sHTG)
- Oct 16th, 2026 5:12 am
Earnings Preview: Swedish Orphan Biovitrum (BIOVF) Q3 Earnings Expected to Decline
- Oct 12th, 2026 7:00 am
Invitation: Sobi's Q3 2026 report
- Oct 8th, 2026 5:20 am
Change in number of shares and votes in Sobi
- Sep 30th, 2026 12:15 am
Sobi to present clinical data on Gamifant® at Histiocyte Society 2026 in Rotterdam
- Sep 24th, 2026 2:53 am
Aytu BioPharma, Inc. (AYTU) Reports Q4 Loss, Beats Revenue Estimates
- Sep 22nd, 2026 3:15 pm
Sobi and Innate announce partnership is now effective following completion of closing conditions
- Sep 16th, 2026 9:28 pm
Sobi Receives US FDA Fast Track Designation for pacritinib in VEXAS Syndrome
- Sep 9th, 2026 11:50 am
Scroll